SLC5A5 and liver cancer: As a result, EVs from Huh7/NIS-Adv donor cells increased 125I uptake of recipient Huh7 and HepG2 human liver cancer cells to 466.3 ± 21.4% and 1095.3 ± 129.1% of respective control levels, and recipient T47D human breast cancer cells to 321.2 ± 26.4% of the control level (Fig. 4c).